Multimodal ultrasound (MMU) is feasible for the diagnosis of neurogenic bladder (NB) in pediatric patients, according to a study published online Jan. 17 in Scientific Reports. Junkui Wang, from the ...

Joe Grantham is a contributor from the UK with a degree in Classical Studies. His love for gaming is only rivaled by a deep passion for medieval history, which often seeps into his articles. With over ...

Applying low-frequency bladder vibration (LFBV) to patients with spinal cord injury (SCI)/neurogenic bladder who developed urinary tract infections (UTIs) during rehabilitation is associated with a ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional ...

Less than half of children with neurogenic bladder diagnosed with febrile UTI in the ED met a commonly recommended definition for UTI. (HealthDay News) — Most children with neurogenic bladder (NGB) ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk for ...

WEDNESDAY, Oct. 15, 2025 (HealthDay News) -- Most children with neurogenic bladder (NGB) and diagnosed with febrile urinary tract infection (UTI) in the emergency department (ED) did not meet a ...

Objective: To evaluate the effectiveness and safety of sacral neuromodulation (SNM) under general anaesthesia in the treatment of neurogenic bladder (NB) in children, and to share clinical experience.

Over 88% reduction in urinary incontinence episodes achieved in low dose cohort at 12 weeks Good tolerability with no systemic side effects First DNA medicine to selectively target, at the local level ...

After decades of limited options, a groundbreaking FDA-approved treatment is opening new doors for people with certain types of bladder cancer. Supported by Johnson & Johnson Bill is a real patient ...

The FDA has signed off on Johnson & Johnson’s highly anticipated bladder cancer drug Inlexzo, marking an advance in the ability to care for patients who otherwise face bladder removal and limited ...